Journey Medical Forecasts Q4 Revenue of $18.9M and 6¢ Loss Ahead of Earnings
Journey Medical is set to report Q4 2025 results on March 25, with analysts forecasting $18.86 million in revenue and a $0.06 per share loss. Full-year 2025 sales estimates have been trimmed to $64.65 million with EPS sliding to a $0.48 loss, following a Q3 revenue miss of 6.5% and EPS shortfall of 136.8%.
1. Q4 2025 Estimates and Full-Year Outlook
Journey Medical will announce Q4 2025 earnings on March 25, with consensus forecasts of $18.86 million in quarterly revenue and a $0.06 loss per share. Full-year 2025 revenue estimates have declined from $65.13 million to $64.65 million over the past 90 days, while EPS projections worsened from a $0.47 loss to a $0.48 loss.
2. Q3 2025 Performance vs. Expectations
In Q3 2025, Journey Medical generated $17.63 million in revenue, missing the $18.85 million consensus by 6.49%. The company reported a $0.09 per share loss compared with an expected $0.04 loss, and the stock fell 15.31% in a single trading session following the results.
3. Analyst Price Targets and Recommendations
Analysts’ 12-month price targets average $13.50, implying a 95.37% upside from current levels, with a high estimate of $16.00 and a low of $12.00. A proprietary valuation model sets fair value at $5.53, suggesting a near 20% downside, while the consensus brokerage rating stands at 2.0, or ‘Outperform.’